88 related articles for article (PubMed ID: 8170219)
1. [Neurological toxicity from pentavalent antimonials during the treatment of visceral leishmaniasis].
Laguna del Estal P; Calabrese S; Zabala JA; Martín T
Med Clin (Barc); 1994 Feb; 102(7):276-7. PubMed ID: 8170219
[No Abstract] [Full Text] [Related]
2. [Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection].
Santos J; Rivero A; Márquez M
An Med Interna; 2000 Oct; 17(10):562-3. PubMed ID: 11109659
[No Abstract] [Full Text] [Related]
3. Antimony-induced cerebellar ataxia.
Khalil EA; Ahmed AE; Musa AM; Hussein MH
Saudi Med J; 2006 Jan; 27(1):90-2. PubMed ID: 16432602
[TBL] [Abstract][Full Text] [Related]
4. [Agranulocytosis caused by glucantime (N-methylglucamine antimoniate) during treatment of kala-azar].
Gutiérrez Rodero F; Moya Jeromini I; Ortiz de la Tabla Ducasse V; Pozuelo González A
Med Clin (Barc); 1985 May; 84(20):840. PubMed ID: 4033266
[No Abstract] [Full Text] [Related]
5. Visceral leishmaniasis and Coombs' positive hemolytic anemia: a rare association in an infant treated with liposomal amphotericin B.
Dilber E; Erduran E; Işik Y
Turk J Pediatr; 2002; 44(4):354-6. PubMed ID: 12458816
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of visceral leishmaniasis in patients with antimonials: is there a maximal dose?].
Llorens Soriano P; Vicente Ull R; Paricio Blasco A; Cervera Juan A; Rubio Rodrigo MJ
An Med Interna; 1999 Nov; 16(11):602. PubMed ID: 10638007
[No Abstract] [Full Text] [Related]
7. Successful treatment of visceral leishmaniasis with fluconazole and allopurinol in a patient with renal failure.
Colakoglu M; Fidan Yaylali G; Yalcin Colakoglu N; Yilmaz M
Scand J Infect Dis; 2006; 38(3):208-10. PubMed ID: 16500783
[TBL] [Abstract][Full Text] [Related]
8. PKDL--a drug related phenomenon?
Croft SL
Indian J Med Res; 2008 Jul; 128(1):10-1. PubMed ID: 18820352
[No Abstract] [Full Text] [Related]
9. [Agranulocytosis caused by glucantime in the treatment of kala-azar].
Gutiérrez Rodero F
Med Clin (Barc); 1986 Mar; 86(10):437. PubMed ID: 3713304
[No Abstract] [Full Text] [Related]
10. [Nephrotic syndrome and acute pancreatitis related to glucantime administration].
Valencia ME; Laguna F; González Lahoz J
An Med Interna; 2000 Jan; 17(1):54. PubMed ID: 10730416
[No Abstract] [Full Text] [Related]
11. Drug regimens for visceral leishmaniasis in Mediterranean countries.
Gradoni L; Soteriadou K; Louzir H; Dakkak A; Toz SO; Jaffe C; Dedet JP; Campino L; Cañavate C; Dujardin JC
Trop Med Int Health; 2008 Oct; 13(10):1272-6. PubMed ID: 18764817
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic observations after meglumine antimoniate therapy for visceral leishmaniasis.
Hantson P; Léonard ED; Crutzen-Fayt MC; Léonard A; Vandercam B; Delaere B; Mahieu P
Pharmacotherapy; 1996; 16(5):869-71. PubMed ID: 8888081
[TBL] [Abstract][Full Text] [Related]
13. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.
Sundar S; More DK; Singh MK; Singh VP; Sharma S; Makharia A; Kumar PC; Murray HW
Clin Infect Dis; 2000 Oct; 31(4):1104-7. PubMed ID: 11049798
[TBL] [Abstract][Full Text] [Related]
14. Conduction defect following pentavalent antimony therapy in visceral leishmaniasis.
Ahasan HA; Chowdhury MA; Azhar MA; Rafiqueuddin AK; Islam F
Trop Doct; 1997 Jan; 27(1):59-61. PubMed ID: 9030031
[No Abstract] [Full Text] [Related]
15. Antimony-based antileishmanial compounds prolong the cardiac action potential by an increase in cardiac calcium currents.
Kuryshev YA; Wang L; Wible BA; Wan X; Ficker E
Mol Pharmacol; 2006 Apr; 69(4):1216-25. PubMed ID: 16418337
[TBL] [Abstract][Full Text] [Related]
16. Sodium stibogluconate and polymorphic ventricular tachycardia.
Baranwal AK; Mandal RN; Singh R; Singhi SC
Indian J Pediatr; 2005 Mar; 72(3):269. PubMed ID: 15812130
[TBL] [Abstract][Full Text] [Related]
17. Sodium stibogluconate.
Shrestha NK
Clin Infect Dis; 2006 Nov; 43(10):1371-2. PubMed ID: 17051510
[No Abstract] [Full Text] [Related]
18. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
Chappuis F; Sundar S; Hailu A; Ghalib H; Rijal S; Peeling RW; Alvar J; Boelaert M
Nat Rev Microbiol; 2007 Nov; 5(11):873-82. PubMed ID: 17938629
[TBL] [Abstract][Full Text] [Related]
19. Does antimony therapy cause bleeding in kala-azar patients and why?
Chowdhury MA; Ahasan HA; Azhar MA; Rafiqueuddin AK; Islam MR; Misbahuddin M; Rashid MU
Trop Doct; 1995 Oct; 25(4):188-9. PubMed ID: 7502336
[No Abstract] [Full Text] [Related]
20. Post-kala-azar dermal leishmaniasis with visceral leishmaniasis: a rare presentation.
Rijal A; Agrawal S; Agarwalla A; Agrawal A; Rijal S
Int J Dermatol; 2005 Jun; 44(6):494-6. PubMed ID: 15941439
[No Abstract] [Full Text] [Related]
[Next] [New Search]
